Research programme: cell-based therapeutics - Q Therapeutics

Drug Profile

Research programme: cell-based therapeutics - Q Therapeutics

Alternative Names: Astrocyte-based therapeutics - Q Therapeutics; Glial cell-based therapeutic (Q-Cells) - Q Therapeutics; Q-Cells; Transplanted human GRPs - Q Therapeutics

Latest Information Update: 20 Dec 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Utah
  • Developer Drexel University College of Medicine; Johns Hopkins University; Q Therapeutics
  • Class Cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Amyotrophic lateral sclerosis; Demyelinating disorders; Spinal cord injuries

Most Recent Events

  • 13 Dec 2017 Preclinical development is ongoing for Amyotrophic lateral sclerosis and Demyelinating disorders in USA
  • 13 Dec 2017 Q Therapeutics enters into a research collaboration with ReproCELL for development of induced pluripotent stem cells for CNS disorders
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Amyotrophic-lateral-sclerosis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top